|drug1403||Enoxaparin sodium Wiki||0.71|
|D016638||Critical Illness NIH||0.09|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.06|
There are 2 clinical trials
Background: Intra-alveolar clotting and alveolar collapse in ARDS is due to alveolar capillaries epithelial and leakage. Subsequently, collapse induces hypoxemia that is resistant to recruitment (RM). Heparin and Streptokinase may prevent or dissolve intra-alveolar fibrin clot respectively helping alveolar re-expansion. We examined and compared the effect of nebulizing Heparin versus Streptokinase on reversing this pathology. Methods: Sixty severe ARDS (PaO2/FiO2<100) patients and failure of RM, prone position (PP) and neuromuscular block (NMB) were partially randomised into Group (I): (n=20) received nebulized Heparin 10000 IU/4h. Group (II): (n=20) received nebulized Streptokinase 250,000 IU/4h. Group (III): (n=20) received conservative management. Randomization to either Heparin or Streptokinase groups was applied to patients whom guardian accepted participation, while those who declined participation were followed-up as a control. The primary outcome was the change in PaO2/FiO2; the secondary outcomes included the change in compliance, plateau pressure, ventilation-off days, coagulation and ICU mortality.
Description: Change in the ratio of arterial oxygen tension to fraction of inspired oxygen from the baseline (day 0, before randomization and or the start of intervention) to day 1 to day 8 after the randomization and or start of intervention.Measure: Change in PaO2/FiO2 ratio Time: daily over eight days
Description: Change in the plateau airway pressure during ventilation from the baseline (day 0, before randomization and or the start of intervention) to day 1 to day 8 after the randomization and or start of intervention.Measure: Change in the plateau pressure Time: daily over eight days
Description: change in volume of the lungs per change in pressure during ventilation from the baseline (day 0, before randomization and or the start of intervention) to day 1 to day 8 after the randomization and or start of intervention.Measure: Change in the pulmonary compliance Time: daily over eight days
Description: Number of patients who are discharged aliveMeasure: ICU survival rate Time: At the end of ICU stay up to one year after the start of recruitment
Description: the total duration the patient stays in ICUMeasure: ICU length of stay Time: At the end of ICU stay up to one year after the start of recruitment
Description: number of patients who required tracheostomyMeasure: Tracheostomy rate Time: During ICU stay up to one month after the start of recruitment
The purpose of this study is to determine if therapeutic dose anticoagulation (experimental group) improves 30-day mortality in participants with COVID-19 compared to those patients receiving the intermediate dose prophylaxis (control group). Following screening, subjects will be randomized 1:1 to intermediate dose prophylaxis or therapeutic dose anticoagulation treatment arms.Treatment will continue for 28 days, followed by a 6 month follow-up period.
Description: Comparison of number of COVID-19 positive patients who have died within 30 days of starting treatment on each treatment armMeasure: 30-day mortality Time: 30 days
Description: Comparison of length of ICU stay in days between each treatment arm.Measure: Length of Intensive Care Unit (ICU) Stay in Days Time: 6 months
Description: Comparison of number of documented VTE, arterial thrombosis and microthrombosis events on each treatment armMeasure: Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events Time: 6 months
Description: Comparison of major and clinically-relevant non-major bleeding events on each treatment arm, as defined by the International Society of Thrombosis and Haemostasis (ISTH) criteria.Measure: Number of major and clinically relevant non-major bleeding events Time: 6 months
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports